Funder
National Institute of Mental Health
Reference91 articles.
1. Efficacy of N-methyl-D-aspartate receptor modulator augmentation in schizophrenia: A meta-analysis of randomised, placebo-controlled trials;Goh;J Psychopharmacol,2021
2. The glutamate/N-methyl-d-aspartate receptor (NMDAR) model of schizophrenia at 35: On the path from syndrome to disease;Javitt;Schizophr Res,2022
3. Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia;Dunayevich;Schizophr Res,2017
4. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: A randomized, double-blind, proof-of-concept study;Umbricht;JAMA Psychiatry,2014
5. Strategies to address challenges in neuroscience drug discovery and development;O’Donnell;Int J Neuropsychopharmacol,2019